Schematic illustration of ErbB receptor structures and dimerization patterns. ErbB, ERB-B2 receptor tyrosine kinase. Antibody-drug conjugates (ADCs) have emerged as a powerful approach to overcome ...
The buzz around HER3-targeting antibody-drug conjugates (ADCs) continues to grow. Only a week after BioNtech got in on the action, Endeavor BioMedicines has secured the rights to Hummingbird ...
BOSTON, April 8, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients ...
SAN DIEGO & HOUSTON & SINGAPORE--(BUSINESS WIRE)--Hummingbird Bioscience (“Hummingbird Bio”), a data-driven precision biotherapeutics company discovering and developing transformative biologic ...
Patients with advanced squamous or nonsquamous NSCLC without a common EGFR-activating mutation whose disease had progressed on previous therapies including platinum-based chemotherapy, immune ...
A new publication shines a spotlight on HER3, a long-overlooked member of the ErbB receptor family, revealing its critical role in cancer progression and resistance to therapy. Once considered a ...
SUZHOU, China, May 6, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on anti-cancer therapies, announced today that poster ...
Elevation Oncology has tapped Lonza’s Synaffix to support the expansion of its pipeline, agreeing to pay up to $368 million to access technology for use in its newly nominated HER3 antibody-drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results